Ozempic vs. Mounjaro for Weight Loss: What the Difference Actually Means for You

What are these drugs, and how do they work?

Ozempic is the brand name for semaglutide at doses approved for type 2 diabetes. Wegovy is semaglutide at a higher dose (2.4 mg weekly) approved specifically for chronic weight management. Mounjaro is the brand name for tirzepatide at doses approved for type 2 diabetes. Zepbound is tirzepatide at doses approved for weight management in adults with obesity or overweight plus a related condition.

Both medications mimic gut hormones that are released after eating. They slow gastric emptying, reduce appetite signals in the brain, and improve how the body handles blood sugar. The key structural difference is their receptor targets:

• Semaglutide activates the GLP-1 receptor only.
• Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — earning the label "dual agonist." [1, 2]

The dual action of tirzepatide is thought to contribute to its greater average weight loss in clinical trials, though the precise mechanisms by which GIP receptor activation adds to metabolic benefit remain an active area of research. 2Ref 2Ma Z, Jin K, Yue M, Chen X, Chen J (2023).Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.Tirzepatide's dual GIP/GLP-1 receptor mechanism and how it differs from GLP-1-only agents like semaglutide

What do the clinical trials show about weight loss?

Individual trials in each drug:

The STEP 1 trial (semaglutide 2.4 mg vs. placebo, 68 weeks) found a mean body weight reduction of approximately 14.9% in the semaglutide group, compared with 2.4% in the placebo group. 3Ref 3Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: semaglutide 2.4 mg produced mean 14.9% body weight reduction vs 2.4% placebo over 68 weeks

The SURMOUNT-1 trial (tirzepatide 5, 10, or 15 mg vs. placebo, 72 weeks) found weight reductions of up to 22.5% at the highest dose in people with obesity but without type 2 diabetes. 4Ref 4Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 trial: tirzepatide produced weight loss of up to 22.5% at 15 mg over 72 weeks in people without T2D

The first direct head-to-head trial:

In 2025, the SURMOUNT-5 trial — the first randomized head-to-head comparison — enrolled 751 adults with obesity but without type 2 diabetes. Participants were assigned to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Tirzepatide produced statistically greater average weight loss: mean waist circumference reduction was 18.4 cm with tirzepatide versus 13.0 cm with semaglutide. 5Ref 5Aronne LJ, Bade Horn D, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators (2025).Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.SURMOUNT-5 head-to-head trial: tirzepatide produced significantly greater weight loss than semaglutide over 72 weeks (waist circumference reduction 18.4 cm vs 13.0 cm) in adults with obesity without T2D

Caveats that matter:

• "On average" hides a wide distribution. Some individuals respond better to semaglutide; others respond better to tirzepatide.
• SURMOUNT-5 was open-label and enrolled people without diabetes — results may not generalize to everyone.
• The trial was funded by Eli Lilly, the manufacturer of tirzepatide.
• Both drugs produce considerably more weight loss than older approved weight-loss medications.

Does semaglutide have a cardiovascular advantage?

This is an area where semaglutide has a longer and stronger evidence base.

The SELECT trial (2023) was a large randomized, placebo-controlled study of semaglutide 2.4 mg in adults with established cardiovascular disease and obesity, but without diabetes. Over a median of nearly 40 months, semaglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20% compared with placebo (6.5% vs. 8.0%; hazard ratio 0.80). This led the FDA to approve an additional indication for Wegovy: reducing the risk of serious cardiovascular events in people with established heart disease and obesity. 6Ref 6Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide reduced major cardiovascular events by 20% (HR 0.80) vs placebo in adults with obesity and established CVD but without diabetes

For tirzepatide, the SURPASS-CVOT trial (2025) compared tirzepatide with dulaglutide (another GLP-1 agent) in over 13,000 adults with type 2 diabetes and atherosclerotic cardiovascular disease. Tirzepatide met the statistical bar for noninferiority but did not demonstrate superiority in reducing major adverse cardiovascular events (12.2% vs. 13.1%; hazard ratio 0.92; p=0.003 for noninferiority). 7Ref 7Nicholls SJ, Pavo I, Bhatt DL, et al. (2025).Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.SURPASS-CVOT: tirzepatide met noninferiority vs dulaglutide for MACE in T2D and ASCVD (HR 0.92, p=0.003 for noninferiority; p=0.09 for superiority) over median 4-year follow-up

In practical terms: semaglutide has a direct placebo-controlled cardiovascular outcomes trial in non-diabetic people with obesity, which Zepbound currently lacks. For someone with established heart disease, this distinction may matter in the conversation with a clinician.

How do the side effects compare?

The side effect profiles of semaglutide and tirzepatide overlap substantially, because both act on the GLP-1 pathway. The most common effects for both are gastrointestinal: nausea, diarrhea, constipation, vomiting, and stomach discomfort. These are typically most pronounced when starting the drug or after a dose increase, and they often diminish over time.

Gallbladder events: A meta-analysis of 76 randomized trials covering over 103,000 patients found that GLP-1 receptor agonists as a class are associated with modestly increased risks of gallbladder and biliary disease — including gallstones and cholecystitis — particularly at higher doses and in trials conducted specifically for weight loss. 8Ref 8He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H (2022).Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.Meta-analysis of 76 RCTs (103,371 patients): GLP-1 agonists associated with increased risk of gallbladder/biliary disease (RR 1.37), especially at higher doses and in weight-loss trials (RR 2.29) Both semaglutide and tirzepatide carry this consideration.

Thyroid precaution: Both medications carry a boxed warning about a type of thyroid tumor (C-cell tumors) observed in rodent studies. This has not been confirmed in humans, but both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. [9, 10]

Heart rate: Both drugs can modestly increase resting heart rate; this is typically small and clinically manageable for most people.

In SURMOUNT-5, the rates of serious adverse events were similar between the two drugs. There is no strong, consistent evidence that one is clearly better tolerated than the other across the general population — individual experience varies widely.

What happens if you stop taking them?

This is one of the most important practical questions. Clinical trial data consistently show that stopping these medications leads to significant weight regain.

The STEP 1 trial extension followed participants for 52 weeks after semaglutide was discontinued. Participants in the semaglutide group, who had lost a mean of 17.3% of body weight during the treatment phase, regained approximately two-thirds of that weight by week 120. Cardiometabolic improvements (blood pressure, HbA1c, lipids) also returned toward baseline. 11Ref 11Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF (2022).Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.STEP 1 extension: participants who stopped semaglutide regained approximately two-thirds of lost weight by week 120, with reversal of cardiometabolic improvements

Similarly, the SURMOUNT-4 trial demonstrated that stopping tirzepatide after 36 weeks of treatment led to substantial weight regain over the following 52 weeks, while continuing on tirzepatide maintained the loss. 12Ref 12Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA (2023).Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.SURMOUNT-4: stopping tirzepatide after 36 weeks led to substantial weight regain; continuing tirzepatide maintained weight loss

This pattern reflects the underlying biology: obesity is a chronic condition involving sustained hormonal and neurological changes. These medications work while they are taken. The ADA's 2025 Standards of Care explicitly recognize this, noting that sudden discontinuation of either drug results in regaining one-half to two-thirds of lost weight within one year. 13Ref 13American Diabetes Association Professional Practice Committee (2024).Standards of Care in Diabetes — 2024.ADA Standards of Care recognize that discontinuation of semaglutide or tirzepatide leads to weight recurrence of one-half to two-thirds within one year Decisions about long-term continuation should be made with a clinician who can assess ongoing benefit, tolerability, and cost.

Practical factors that often determine which drug you get

Even if trial data shows tirzepatide produces somewhat greater average weight loss, several real-world factors frequently determine which medication a clinician prescribes:

Insurance and cost. Without coverage, both drugs cost several hundred to over a thousand dollars per month. Insurance prior authorization criteria, your plan's formulary position, and manufacturer patient-assistance programs can make one drug far more accessible than the other — sometimes the only viable option.

Your specific diagnosis. The FDA labels are distinct. Ozempic and Mounjaro are indicated for type 2 diabetes. Wegovy and Zepbound are indicated for chronic weight management. Insurance coverage criteria often hinge on your diagnosis and whether prior weight-loss treatments have been tried.

Cardiovascular history. As noted above, semaglutide's SELECT trial data may make it a stronger choice for someone with established cardiovascular disease who needs both weight management and cardiovascular risk reduction.

Prior response or intolerance. If you have tried one drug and experienced intolerable side effects or poor weight-loss response, a trial of the other is clinically reasonable.

Supply and availability. Both drugs have experienced shortages at various points since their approvals. Real-world availability at a given time can narrow the decision.

None of these factors can be weighed well without a clinician who knows your full medical history, your labs, and your goals.

These medications work best alongside lifestyle changes

Both semaglutide and tirzepatide were studied in combination with lifestyle intervention — diet and physical activity guidance — in the pivotal trials that established their efficacy. They reduce appetite and make behavior change more sustainable for many people, but they do not substitute for eating patterns that support a caloric deficit or for regular movement.

Clinical programs with the strongest weight-loss outcomes pair these medications with behavioral and nutritional support. The WHO's 2020 physical activity guidelines recommend at least 150 to 300 minutes of moderate-intensity aerobic activity per week for health benefit 14Ref 14Bull FC, Al-Ansari SS, Biddle S, et al. (2020).World Health Organization 2020 guidelines on physical activity and sedentary behaviour.WHO recommends 150–300 minutes of moderate-intensity aerobic activity weekly for adults as a health standard applicable regardless of weight-loss pharmacotherapy, and that recommendation applies regardless of which, if any, weight-loss medication a person uses.

Both drugs also require ongoing clinical management: dose titration during initiation, monitoring for side effects, periodic labs, and shared decision-making about whether and how long to continue. They are not one-and-done treatments.